Literature review · Metabolism & weight

AOD-9604

Mouse lipid-metabolism findings should be read alongside the unsuccessful human obesity development programme. A safety-focused publication is not proof of weight-loss efficacy.

By HeartPep · Reviewed · 3 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The sources span mouse experiments, a sponsor-associated human safety summary and an FDA assessment of the reported clinical programme.

Identity & scope

AOD-9604 is a modified growth-hormone C-terminal fragment. It is distinct from full-length growth hormone and should not be equated with an unspecified supplier label such as H Frag.

Catalogue labels covered: AOD-9604.

What the research shows

  • Mouse experiments implicated beta-adrenergic signalling in effects on fat metabolism [1].
  • A six-trial safety summary reported several reassuring monitored outcomes but did not establish clinical efficacy [2].
  • FDA's assessment describes a larger obesity trial that did not show a significant advantage over placebo for its principal weight-loss comparison [3].

Critical interpretation

Why the clinical comparison outweighs the animal headline

The mouse paper investigated a biological pathway; the obesity programme asked whether that pathway produced an advantage over placebo in people. FDA describes an unsuccessful primary comparison in the larger study. Weight lost inside an active group is not the same as weight loss caused by the intervention, because the comparison group also received a structured programme. A favourable animal finding or subgroup cannot replace that principal clinical comparison. Incomplete publication of the original efficacy data limits further independent checking, rather than converting a negative result into positive evidence. [1] [3]

Safety summaries and agency assessments have different roles

The 2013 publication concentrates on selected safety measurements across heterogeneous trials, including very short exposures. Its reassuring interpretation does not establish that every formulation is harmless or that uncommon events were excluded. The FDA briefing is a regulatory evidence assessment, not a new randomized trial or a final approval decision. It raises questions about the adequacy of the available evidence and certain preclinical methods. Readers should keep the study preparation, observation period and outcome question attached to each claim, rather than treating the phrase growth-hormone fragment as a transferable safety assurance. [2] [3]

Limitations & uncertainties

  • The major negative trial was not available as a full peer-reviewed efficacy report in the agency assessment.
  • Historical investigational oral or intravenous preparations do not validate a catalogue vial, nasal preparation or proposed clinical use.

Open research questions

  • Can complete participant-level and adverse-event reporting from the historical programme be independently examined?
  • What additional evidence would be needed for any specific formulation or proposed indication?

Selected papers & source records

Download bibliography
Animal studyNamed compoundAbstract / record checked

1. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice (opens in a new tab)

Heffernan M, Summers RJ, Thorburn A, et al. (2001). Endocrinology. DOI: 10.1210/endo.142.12.8522 (opens in a new tab) · PMID 11713213

Design & population
14-day experiments in obese mice and beta-3-adrenoceptor knockout mice.
What the study found
Weight and fat effects in the obese mice differed from knockout animals, supporting a role for beta-adrenergic signalling in the model.
Limits on interpretation
Species-specific experimental findings do not establish a human weight-loss effect.
Human studyNamed compoundAbstract / record checked

2. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (opens in a new tab)

Stier H, Vos E, Kenley D (2013). Journal of Endocrinology and Metabolism. DOI: 10.4021/jem157w (opens in a new tab)

Design & population
Summary of six placebo-controlled clinical studies, with different exposure durations and study preparations.
What the study found
The authors reported no detected anti-AOD9604 antibodies in tested participants and no adverse changes in selected IGF-1 and glucose measures.
Limits on interpretation
Safety-focused, sponsor-associated reporting with limited detail. It does not demonstrate weight-loss efficacy or exclude uncommon, delayed or formulation-specific harm.
Technical referenceNamed compoundFull text consulted

3. FDA evaluation of AOD-9604-related bulk drug substances (opens in a new tab)

U.S. Food and Drug Administration (2024). Pharmacy Compounding Advisory Committee briefing document.

Design & population
Agency evidence assessment, including the developer's report of the 24-week OPTIONS obesity study.
What the study found
FDA found that the reported primary weight-loss comparison did not significantly favour AOD-9604 over placebo and identified substantial evidence limitations.
Limits on interpretation
This is an agency assessment, not the original trial report or a final marketing-authorisation decision. The underlying efficacy report was not located as a full medical-journal publication.

Search & review scope

Targeted primary literature and agency-document review, retaining the negative clinical finding.. Checked 9 November 2026.

Mouse metabolic experiment, human safety publication and agency assessment of the historical obesity programme.

Not a systematic review. The original major efficacy trial was not reviewed in full; its result is attributed to FDA's assessment of the developer's report.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov AOD9604 obesity randomized trial negative
  • AOD9604 Stier Vos Kenley 2013 10.4021/jem157w safety tolerability human
  • site.fda.gov AOD-9604 2024 502 weight loss

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. AOD-9604: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/aod-9604.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes